Validation of the use of Middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin.
about
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitroPrevalence of Extensively Drug Resistant Tuberculosis among Archived Multidrug Resistant Tuberculosis Isolates in Zimbabwe.Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis.Current perspectives on drug susceptibility testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems.Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing of Mycobacterium tuberculosis.Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance.Extensively drug-resistant tuberculosis: new strains, new challenges.Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin.Inhibition of the sole type I signal peptidase of Mycobacterium tuberculosis is bactericidal under replicating and nonreplicating conditions.Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosis.Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex.
P2860
Q24656698-26BF60F9-D268-44FF-A70C-43EE389BEB7EQ33745972-1285D302-D55C-48A2-82A8-4EF6FBEC1430Q34431677-B93A9699-60FC-46BA-B78C-81C8914A013AQ36359595-BC1CD0CB-D242-427C-9E80-A08A70176EA5Q36482760-3F4619DA-3FC9-4282-9CE8-0D8D6EC8CC64Q36773017-E23DC11A-B315-41E9-BF7B-F16358EEBA91Q37187468-BF2F4874-1B3B-4383-AC32-92FA9AE1195DQ37291363-02A9A211-DDBF-4AB6-AC49-10BDB60571F1Q38898564-85BF1C04-50E7-4455-9BE9-670AD6AC247CQ42152549-EE7D8317-D8ED-40B1-9279-E83EFCB6FDCAQ42432121-623FACB0-DD6C-44C3-9B7C-E35CCC8B31B3Q42613641-C2B54A0E-9BEB-4977-BCE8-539F788D1D38
P2860
Validation of the use of Middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Validation of the use of Middl ...... tuberculosis to levofloxacin.
@en
type
label
Validation of the use of Middl ...... tuberculosis to levofloxacin.
@en
prefLabel
Validation of the use of Middl ...... tuberculosis to levofloxacin.
@en
P2093
P2860
P1476
Validation of the use of Middl ...... tuberculosis to levofloxacin.
@en
P2093
Cynthia A Sanders
Edward P Desmond
Rachel R Nieda
P2860
P304
P356
10.1128/JCM.42.11.5225-5228.2004
P407
P577
2004-11-01T00:00:00Z